OTCMKTS:RLMD

Relmada Therapeutics Stock News

Healthcare > Biotechnology

Buy RLMD

*Your capital is at risk

$6.33

-0.0900 (-1.40%)

At Close: Jun 03, 2026

Relmada Therapeutics Inc Is Under Investigation By The Schall Law Firm For Possible Securities Breaches And Impacted Investors Are Encouraged To Initiate Dialogues

05:45pm, Friday, 19'th Jul 2024

LOS ANGELES, CA / ACCESSWIRE / July 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Relmada Therapeut

The Schall Law Firm Is Investigating Relmada Therapeutics Inc For Potential Securities Violations And Urges Affected Investors To Start Conversations

05:15pm, Thursday, 18'th Jul 2024

LOS ANGELES, CA / ACCESSWIRE / July 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Relmada Therapeut

Relmada Therapeutics Inc Is Under Examination For Possible Securities Breaches By The Schall Law Firm, Impacted Investors Are Encouraged To Initiate Dialogues

03:30pm, Wednesday, 17'th Jul 2024

LOS ANGELES, CA / ACCESSWIRE / July 17, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Relmada Therapeut

The Schall Law Firm Encourages Affected Investors To Start Conversation, Relmada Therapeutics Inc Is Under Scrutiny For Potential Securities Breaches

03:45pm, Tuesday, 16'th Jul 2024

LOS ANGELES, CA / ACCESSWIRE / July 16, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Relmada Therapeut

Relmada Therapeutics Inc Under Investigation By The Schall Law Firm For Possible Securities Violations Urging Impacted Investors To Initiate Dialogue

03:15pm, Monday, 15'th Jul 2024

LOS ANGELES, CA / ACCESSWIRE / July 15, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Relmada Therapeut

Relmada Therapeutics Inc Under Probe By The Schall Law Firm For Possible Securities Breaches Urges Affected Investors To Start Conversation

07:00pm, Saturday, 13'th Jul 2024

LOS ANGELES, CA / ACCESSWIRE / July 13, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Relmada Therapeut

Potential Securities Violations By Relmada Therapeutics Inc Are Under Investigation By The Schall Law Firm Encouraging Impacted Investors To Initiate Dialogue

06:45pm, Friday, 12'th Jul 2024

LOS ANGELES, CA / ACCESSWIRE / July 12, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Relmada Therapeut

Relmada Therapeutics Inc Under Scrutiny By The Schall Law Firm For Potential Securities Breaches Urging Affected Investors To Initiate Conversation

02:15pm, Thursday, 11'th Jul 2024

LOS ANGELES, CA / ACCESSWIRE / July 11, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Relmada Therapeut

Relmada Therapeutics Inc Is Under Investigation By The Schall Law Firm For Possible Securities Violations And Impacted Investors Are Urged To Establish Dialogue

02:30pm, Wednesday, 10'th Jul 2024

LOS ANGELES, CA / ACCESSWIRE / July 10, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Relmada Therapeut

Relmada Therapeutics Inc Is Being Probed By The Schall Law Firm For Potential Securities Breaches And Affected Investors Are Encouraged To Set Up Communication

03:00pm, Tuesday, 09'th Jul 2024

LOS ANGELES, CA / ACCESSWIRE / July 9, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Relmada Therapeuti

Relmada Therapeutics Inc Is Under Investigation By The Schall Law Firm For Possible Securities Violations And Impacted Investors Are Urged To Establish Communication

01:45pm, Monday, 08'th Jul 2024

LOS ANGELES, CA / ACCESSWIRE / July 8, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Relmada Therapeuti

The Schall Law Firm Begins Probe Into Relmada Therapeutics Inc For Suspected Securities Violations And Promotes Investors With Losses To Get In Touch

11:00am, Sunday, 07'th Jul 2024

LOS ANGELES, CA / ACCESSWIRE / July 7, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Relmada Therapeuti

Investigation Into Possible Securities Infringements By Relmada Therapeutics Inc Is Being Conducted By The Schall Law Firm And It Invites Affected Investors To Reach Out

11:00am, Saturday, 06'th Jul 2024

LOS ANGELES, CA / ACCESSWIRE / July 6, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Relmada Therapeuti

The Schall Law Firm Initiates Examination Into Relmada Therapeutics Inc For Potential Securities Breaches And Encourages Impacted Investors To Establish Contact

04:00pm, Friday, 05'th Jul 2024

LOS ANGELES, CA / ACCESSWIRE / July 5, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Relmada Therapeuti

The Schall Law Firm Investigates Relmada Therapeutics Inc For Potential Securities Breaches And Encourages Impacted Investors To Connect

12:30pm, Wednesday, 03'rd Jul 2024

LOS ANGELES, CA / ACCESSWIRE / July 3, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Relmada Therapeuti

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by